KR20080110882A - ＰＴＰａｓｅ의 티아디아졸리디논 억제제 - Google Patents
ＰＴＰａｓｅ의 티아디아졸리디논 억제제 Download PDFInfo
- Publication number
- KR20080110882A KR20080110882A KR1020087026637A KR20087026637A KR20080110882A KR 20080110882 A KR20080110882 A KR 20080110882A KR 1020087026637 A KR1020087026637 A KR 1020087026637A KR 20087026637 A KR20087026637 A KR 20087026637A KR 20080110882 A KR20080110882 A KR 20080110882A
- Authority
- KR
- South Korea
- Prior art keywords
- hydroxy
- thiadiazolidin
- phenyl
- trioxo
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Cc(c(*)c1)ccc1I Chemical compound Cc(c(*)c1)ccc1I 0.000 description 8
- KAOSIMLDPJKOSL-UHFFFAOYSA-N CC(C)(C)CCc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O Chemical compound CC(C)(C)CCc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O KAOSIMLDPJKOSL-UHFFFAOYSA-N 0.000 description 1
- YCLUOMUJKNSSRQ-UHFFFAOYSA-N CC(C1N(CC(N2)O)S2(=O)=O)C=C(CC(Cc2ccccc2)C(c2ccccc2)=O)C=C1O Chemical compound CC(C1N(CC(N2)O)S2(=O)=O)C=C(CC(Cc2ccccc2)C(c2ccccc2)=O)C=C1O YCLUOMUJKNSSRQ-UHFFFAOYSA-N 0.000 description 1
- QDHYAFCDUIZMJI-UHFFFAOYSA-N CC(CCc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O)C#N Chemical compound CC(CCc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O)C#N QDHYAFCDUIZMJI-UHFFFAOYSA-N 0.000 description 1
- DTDKKGLIPCZOHV-UHFFFAOYSA-N CCC(C(C1=CCC(Cc(cc2)cc(O)c2N(CC(N2)=O)S2(=O)=O)CCC1)=O)=C Chemical compound CCC(C(C1=CCC(Cc(cc2)cc(O)c2N(CC(N2)=O)S2(=O)=O)CCC1)=O)=C DTDKKGLIPCZOHV-UHFFFAOYSA-N 0.000 description 1
- UAAAOPWNJBJAQU-UHFFFAOYSA-N CN(Cc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O)S(c1ccccc1)(=O)=O Chemical compound CN(Cc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O)S(c1ccccc1)(=O)=O UAAAOPWNJBJAQU-UHFFFAOYSA-N 0.000 description 1
- FBXCBZHXFIOBNY-UHFFFAOYSA-N C[Si+](C)(C)CCOC(COc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O)=O Chemical compound C[Si+](C)(C)CCOC(COc(cc1)cc(O)c1N(CC(N1)=O)S1(=O)=O)=O FBXCBZHXFIOBNY-UHFFFAOYSA-N 0.000 description 1
- XFIWJWMPKUOTOQ-UHFFFAOYSA-N OC(CN1c(ccc(OCC(O)=O)c2)c2O)NS1(=O)=O Chemical compound OC(CN1c(ccc(OCC(O)=O)c2)c2O)NS1(=O)=O XFIWJWMPKUOTOQ-UHFFFAOYSA-N 0.000 description 1
- ICYKVLDWZLQDDR-UHFFFAOYSA-N OC1=CC(CCCC(CCC2)S2(=O)=O)CC=C1N(CC(N1)=O)S1(=O)=O Chemical compound OC1=CC(CCCC(CCC2)S2(=O)=O)CC=C1N(CC(N1)=O)S1(=O)=O ICYKVLDWZLQDDR-UHFFFAOYSA-N 0.000 description 1
- YZFNYGSLIJIOIQ-UHFFFAOYSA-N Oc(cc(C1COCC1)cc1)c1N(CC(N1)=O)S1(=O)=O Chemical compound Oc(cc(C1COCC1)cc1)c1N(CC(N1)=O)S1(=O)=O YZFNYGSLIJIOIQ-UHFFFAOYSA-N 0.000 description 1
- AQCDRLQSYZPGAF-UHFFFAOYSA-N Oc(cc(CC1CCCCC1)cc1)c1N(CC(N1)=O)S1(=O)=O Chemical compound Oc(cc(CC1CCCCC1)cc1)c1N(CC(N1)=O)S1(=O)=O AQCDRLQSYZPGAF-UHFFFAOYSA-N 0.000 description 1
- YUTUVLLTYSPYAD-UHFFFAOYSA-N Oc(cc(CCCCS(c1ccccc1)(=O)=O)cc1)c1N(CC(N1)=O)S1(=O)=O Chemical compound Oc(cc(CCCCS(c1ccccc1)(=O)=O)cc1)c1N(CC(N1)=O)S1(=O)=O YUTUVLLTYSPYAD-UHFFFAOYSA-N 0.000 description 1
- NTZGPOFCVVGEGE-VIFPVBQESA-N Oc(cc(C[C@H](CC1)NC1=O)cc1)c1N(CC(N1)=O)S1(=O)=O Chemical compound Oc(cc(C[C@H](CC1)NC1=O)cc1)c1N(CC(N1)=O)S1(=O)=O NTZGPOFCVVGEGE-VIFPVBQESA-N 0.000 description 1
- VYVLSXSBIBQPSK-UHFFFAOYSA-N Oc(cc(cc1)-c(cc2)cc(O)c2N(CC(N2)=O)S2(=O)=O)c1N(CC(N1)=O)S1(=O)=O Chemical compound Oc(cc(cc1)-c(cc2)cc(O)c2N(CC(N2)=O)S2(=O)=O)c1N(CC(N1)=O)S1(=O)=O VYVLSXSBIBQPSK-UHFFFAOYSA-N 0.000 description 1
- ZTFRVTBDSRTWCP-UHFFFAOYSA-N Oc(cc(cc1)-c2cnc[s]2)c1N(CC(N1)=O)S1(=O)=O Chemical compound Oc(cc(cc1)-c2cnc[s]2)c1N(CC(N1)=O)S1(=O)=O ZTFRVTBDSRTWCP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78850206P | 2006-03-31 | 2006-03-31 | |
| US60/788,502 | 2006-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080110882A true KR20080110882A (ko) | 2008-12-19 |
Family
ID=38458259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087026637A Withdrawn KR20080110882A (ko) | 2006-03-31 | 2007-03-29 | ＰＴＰａｓｅ의 티아디아졸리디논 억제제 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8084448B2 (https=) |
| EP (1) | EP2038267A2 (https=) |
| JP (1) | JP2009532379A (https=) |
| KR (1) | KR20080110882A (https=) |
| CN (1) | CN101421256A (https=) |
| AU (1) | AU2007233251A1 (https=) |
| BR (1) | BRPI0710182A2 (https=) |
| CA (1) | CA2647472A1 (https=) |
| MX (1) | MX2008012598A (https=) |
| RU (1) | RU2008143053A (https=) |
| WO (1) | WO2007115058A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| CA2629819A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
| CA2630448A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors |
| UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AU2010327597B2 (en) * | 2009-12-04 | 2014-06-19 | Nissan Chemical Industries, Ltd. | 2-Pyridone compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP5809157B2 (ja) * | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JPWO2012147516A1 (ja) * | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| EP2703393A4 (en) * | 2011-04-28 | 2014-09-24 | Mochida Pharm Co Ltd | CYCLIC AMIDE DERIVATIVE |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9216988B2 (en) * | 2011-12-22 | 2015-12-22 | Genentech, Inc. | Benzyl sulfonamide derivatives as RORc modulators |
| CN102659539A (zh) * | 2012-05-15 | 2012-09-12 | 北京化工大学 | 一种由α,β-不饱和酰氯制备二氢查尔酮类化合物的方法 |
| WO2014081718A1 (en) | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| WO2017165139A1 (en) | 2016-03-25 | 2017-09-28 | St. Jude Children's Research Hospital | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor |
| AU2019200683B2 (en) * | 2018-02-01 | 2024-05-30 | The University Of Sydney | Anti-cancer compounds |
| EA202092305A1 (ru) * | 2018-03-27 | 2020-12-07 | Нейропор Терапиз, Инк. | Соединения в качестве модуляторов сигнализации tlr2 |
| BR112020026086A2 (pt) * | 2018-06-21 | 2021-03-23 | Calico Life Sciences Llc | inibidores da proteína tirosina fosfatase e métodos de uso destes |
| WO2020035019A1 (zh) | 2018-08-17 | 2020-02-20 | 浙江海正药业股份有限公司 | 吲唑胺类衍生物及其制备方法和其在医药上的用途 |
| IL286373B2 (en) * | 2019-03-14 | 2026-03-01 | Calico Life Sciences Llc | Protein tyrosine phosphate inhibitor compounds and uses thereof |
| EP4073242A4 (en) | 2019-12-12 | 2024-01-03 | Kumquat Biosciences Inc. | Compositions and methods for potentiating immune activity |
| PE20241474A1 (es) * | 2021-11-23 | 2024-07-17 | Kumquat Biosciences Inc | Compuestos que contienen heteroatomos y usos de estos |
| PE20250780A1 (es) * | 2022-02-02 | 2025-03-14 | Nerio Therapeutics Inc | Inhibidores de proteina tirosina fosfatasa y usos de estos |
| JP2025513882A (ja) * | 2022-04-14 | 2025-04-30 | ネリオ セラピューティクス，インク． | タンパク質チロシンホスファターゼ阻害剤およびその使用 |
| EP4522594A4 (en) * | 2022-05-13 | 2026-04-22 | Mondego Bio Lda A Limited Liability Company By Quotas Soc Por Quotas | PTPN2 INHIBITORS |
| CN117658947B (zh) * | 2022-09-06 | 2026-03-06 | 杭州中美华东制药有限公司 | 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物 |
| AR131413A1 (es) * | 2022-12-21 | 2025-03-19 | Bristol Myers Squibb Co | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso |
| CN116283467B (zh) * | 2023-01-18 | 2024-06-11 | 四川大学 | 一种合成二芳基烷基甲烷的方法 |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| CN119818693A (zh) * | 2023-10-13 | 2025-04-15 | 华东师范大学 | 一种用于前药给药系统的可裂解支链连接体化合物及其制备和应用 |
| US20260008777A1 (en) * | 2024-07-08 | 2026-01-08 | Bristol-Myers Squibb Company | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
| WO2026037253A1 (zh) * | 2024-08-10 | 2026-02-19 | 杭州英创医药科技有限公司 | 作为ptpn抑制剂的化合物 |
| US20260092058A1 (en) | 2024-09-30 | 2026-04-02 | St. Jude Children's Research Hospital, Inc. | Small Molecule Degraders and Fluorescent Probes of PXR |
| CN119220146A (zh) * | 2024-10-24 | 2024-12-31 | 山东三佳聚合高分子材料有限公司 | 一种新型隔热保温涂料 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2381397A (en) * | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| KR100868587B1 (ko) * | 2002-04-03 | 2008-11-12 | 노파르티스 아게 | Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체 |
| GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
| EP1594497B1 (en) * | 2002-12-30 | 2009-05-27 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| CA2630448A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,1,3-trioxo-1,2,5-thiadiazolidines and their use as ptp-ases inhibitors |
| CA2629819A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
-
2007
- 2007-03-29 CA CA002647472A patent/CA2647472A1/en not_active Abandoned
- 2007-03-29 AU AU2007233251A patent/AU2007233251A1/en not_active Abandoned
- 2007-03-29 MX MX2008012598A patent/MX2008012598A/es not_active Application Discontinuation
- 2007-03-29 CN CNA2007800120054A patent/CN101421256A/zh active Pending
- 2007-03-29 BR BRPI0710182-1A patent/BRPI0710182A2/pt not_active Application Discontinuation
- 2007-03-29 EP EP20070780835 patent/EP2038267A2/en not_active Withdrawn
- 2007-03-29 US US12/295,545 patent/US8084448B2/en not_active Expired - Fee Related
- 2007-03-29 JP JP2009503258A patent/JP2009532379A/ja active Pending
- 2007-03-29 KR KR1020087026637A patent/KR20080110882A/ko not_active Withdrawn
- 2007-03-29 RU RU2008143053/04A patent/RU2008143053A/ru not_active Application Discontinuation
- 2007-03-29 WO PCT/US2007/065421 patent/WO2007115058A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007115058A2 (en) | 2007-10-11 |
| CN101421256A (zh) | 2009-04-29 |
| WO2007115058A3 (en) | 2008-03-20 |
| US8084448B2 (en) | 2011-12-27 |
| BRPI0710182A2 (pt) | 2012-08-07 |
| AU2007233251A1 (en) | 2007-10-11 |
| RU2008143053A (ru) | 2010-05-10 |
| CA2647472A1 (en) | 2007-10-11 |
| US20090181928A1 (en) | 2009-07-16 |
| EP2038267A2 (en) | 2009-03-25 |
| MX2008012598A (es) | 2008-10-10 |
| JP2009532379A (ja) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080110882A (ko) | ＰＴＰａｓｅ의 티아디아졸리디논 억제제 | |
| AU2006321902B2 (en) | 1-orthofluorophenyl substituted 1, 2 , 5-thiazolidinedione derivatives as PTP-as inhibitors | |
| AU2006321905B2 (en) | Thiadiazole derivatives as antidiabetic agents | |
| JP2010043130A (ja) | Ｐｔｐアーゼインヒビターとしての５−置換１，１−ジオキソ−‘１，２，５！チアゾリジン−３−オン誘導体 | |
| US8119666B2 (en) | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | |
| BRPI0619547A2 (pt) | 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas | |
| MX2008007349A (es) | Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-as | |
| MX2008007352A (en) | l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20081030 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |